Does Rallies show 13F holders for ATRA?

Yes. Rallies tracks hedge fund and 13F ownership data for ATRA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ATRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATRA. It does not provide personalized investment advice.

ATRA (Atara Biotherapeutics, Inc) Stock Analysis - Hedge Fund Holdings

Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRA trades at $9.34 with a market cap of $82.44M and a P/E ratio of 3.63. ATRA moved +0.96% today. Year to date, ATRA is -43.95%; over the trailing twelve months it is +35.00%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ATRA stock?

Hedge funds tracked by Rallies that own ATRA include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atara Biotherapeutics, Inc.

ATRA Key Metrics

Key financial metrics for ATRA
Metric	Value
Price	$9.34
Market Cap	$82.44M
P/E Ratio	3.63
EPS	$2.61
Dividend Yield	0.00%
52-Week High	$19.15
52-Week Low	$3.92
Volume	42
Avg Volume	0
Revenue (TTM)	$120.77M
Net Income	$32.69M
Gross Margin	0.00%

Top Hedge Funds Holding ATRA

Redmile Group holds 441.70K shares of ATRA, changed +0.00% as of Mar 31, 2026.

Latest ATRA News

Atara Biotherapeutics Upgraded to Buy with $13 Target After FDA Clears Tabelecleucel Path — May 8, 2026
Atara Secures FDA Resubmission Path for Tabelecleucel BLA, Preserves Review Timeline — May 7, 2026
Atara Seeks FDA Type A Meeting, Submits Efficacy Data for Tab-cel Resubmission — Mar 3, 2026

Recent ATRA Insider Trades

Nguyen AnhCo sold 5.24K (~$47.84K) on May 18, 2026.
Grant-Huerta Yanina sold 2.41K (~$22.04K) on May 18, 2026.
Panacea Innovation Ltd sold 313.45K (~$3.17M) on May 7, 2026.

ATRA Analyst Consensus

2 analysts cover ATRA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.

Common questions about ATRA

Who owns ATRA stock?: Hedge funds tracked by Rallies that own ATRA include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atara Biotherapeutics, Inc.
Does Rallies show 13F holders for ATRA?: Yes. Rallies tracks hedge fund and 13F ownership data for ATRA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ATRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATRA. It does not provide personalized investment advice.